title: Intravitreal bevacizumab (Avastin) injection in retinitis pigmentosa.
abstract: OBJECTIVE
  To evaluate and report the effectiveness, visual, anatomical, and clinical outcome of intravitreal bevacizumab (Avastin) injection in patients with retinitis pigmentosa (RP).
  
  
  METHODS
  Our prospective study included 13 eyes of 7 patients (4 women and 3 men) in the age range of 25-69 years (mean 44.14 years) with cystoid macular edema (CME) secondary to RP. Intravitreal bevacizumab at a dose of 1.25 mg/0.05 ml was injected via a 28-gauge needle. The response rate to treatment was monitored functionally by visual acuity assessment and anatomically using the optical coherence tomography.
  
  
  RESULTS
  The baseline mean central macular thickness was 370.15 microm (range 245-603 microm. The central macular thickness decreased to 142.53 microm (range 124-168 microm) after bevacizumab injections. The pre- and post-treatment visual acuity ranges were 5/400-20/100 and 20/200-20/63, respectively.
  
  
  CONCLUSIONS
  Our data reveal that intravitreal bevacizumab administration is effective for the treatment of CME in RP. Further studies with a larger population and longer follow-up period are warranted to assess the efficacy of the treatment.
authors.affiliation: Bilim University, Istanbul, Turkey. erdalyuzbasioglu@mynet.com
authors.forename: Erdal
authors.initials: E
authors.lastname: Yuzbasioglu
authors.forename: Ozgur
authors.initials: O
authors.lastname: Artunay
authors.forename: Rifat
authors.initials: R
authors.lastname: Rasier
authors.forename: Alper
authors.initials: A
authors.lastname: Sengul
authors.forename: Halil
authors.initials: H
authors.lastname: Bahcecioglu
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008266:Macula Lutea / Q000473:pathology; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012174:Retinitis Pigmentosa / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab